A phase II clinical trial has shown that otamixaban, a selective inhibitor of factor Xa, reduces the risk of death or other adverse cardiovascular outcomes in patients with acute coronary syndromes.

Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a plasma elimination half-life of 12 hours and has been administered in a twice-daily dosing ...

A big advance Any factor XI agent that reaches the market would likely represent an important advance over drugs called ...

Apixaban is currently indicated in Europe for the prevention of VTE in patients who have undergone total knee replacement or total hip replacement. Apixaban is also being investigated in Phase III ...

In the case described here, treatment with the selective factor Xa inhibitor fondaparinux led to rapid healing of all the patient’s lesions. Dr. med. Bijan Koushk-Jalali, Dr. med. Christian ...